ESR1 and ovarian carcinoma: Systematic reviews and meta-analyses have previously been done to determine the effects of ER expression on clinical outcomes of patients with ovarian cancer [25, 26]; however, none of these studies addressed the use of different detection methods and different antibodies in different studies.